Small Molecule Degraders and Fluorescent Probes of PXR
Summary
USPTO published patent application US20260092058A1 disclosing compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention relates to decreasing adverse drug reactions associated with administration of anticancer agents, antibacterial agents, non-steroidal anti-inflammatory agents, or anticonvulsant agents. Application No. 18902844 was filed September 30, 2024.
What changed
USPTO published patent application US20260092058A1 disclosing novel small molecule degraders and fluorescent probes targeting the pregnane X receptor (PXR). The application covers heterocyclic compounds (CPC: C07D 417/14, C07F 5/022) and methods for using these compounds to decrease adverse drug reactions associated with anticancer agents, antibacterial agents, NSAIDs, or anticonvulsants. Inventors include Taosheng Chen, Andrew Huber, Young-Hwan Jung, Yongtao Li, and Wenwei Lin. Application No. 18902844 was filed September 30, 2024.
This is a patent application publication only and does not impose compliance obligations on third parties. Entities conducting research in PXR-targeted therapeutics or drug interaction mitigation may wish to review this application to assess potential freedom-to-operate considerations. No regulatory deadlines, penalties, or mandatory compliance requirements are associated with this document.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Small Molecule Degraders and Fluorescent Probes of PXR
Application US20260092058A1 Kind: A1 Apr 02, 2026
Inventors
Taosheng Chen, Andrew Huber, Young-Hwan Jung, Yongtao Li, Wenwei Lin
Abstract
The present disclosure in one aspect, relates to compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention further relates to the use of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse drug reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, or an anticonvulsant agent. The invention, in one aspect, further relates to compounds, compositions, and methods for identifying PXR ligands. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
CPC Classifications
C07D 417/14 A61K 47/55 C07F 5/022 G01N 21/6428 G01N 33/5308 G01N 2021/6439
Filing Date
2024-09-30
Application No.
18902844
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.